Clinical Trials · NCT05694819
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- National Cancer Center Hospital East
- Enrollment
- 57
- Start date
- Apr 2020
- Locations
- 12 sites, Japan
- Primary endpoint
- Darolutamide monotherapy group: Objective response rate(ORR) assessed by investigators